Our lead compound, known as OLX07010, is a small molecule inhibitor of tau self-association which has demonstrated in vivo efficacy in two transgenic mouse models of tauopathy, htau and JNPL3, representing tau aggregation in AD and inherited tauopathies, respectively. 

The htau model expresses all 6 human CNS tau isoforms, without the mutations that are found in inherited forms of tauopathy, in place of murine tau. JNPL3 mice express the human tau 4R0N isoform with the P301L mutation that can cause FTD and PSP. The blinded efficacy and confirmatory studies were independently performed by the late Peter Davies, Ph.D., Director, Litwin-Zucker Center for Alzheimer’s Disease & Memory Disorders, The Feinstein Institute for Medical Research, Northwell Health. Oligomerix is evaluating OLX07010 for both Rare tauopathies and AD and is planning first-in-human clinical trials in 2022.